Hanism of activation and insights into differential inhibitor sensitivity. Most cancers Mobile eleven(3):21727. sixty two. Chang S, et al. (2012) Style, synthesis, and biological analysis of novel conformationally constrained inhibitors focusing on epidermal expansion element receptor threonine790 methionine790 mutant. J Med Chem fifty five(6):2711723. sixty three. Dey JH, et al. (2010) Concentrating on fibroblast expansion factor receptors blocks PI3KAKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Most cancers Res 70(10):Glucoraphanin web 4151162.sixty four. Cole C, et al. (2010) Inhibition of FGFR2 and FGFR1 raises cisplatin sensitivity in ovarian cancer. Cancer Biol Ther 10(five):49504. sixty five. Sewell JM, Macleod KG, Ritchie A, Smyth JF, Langdon SP (2002) Targeting the EGF receptor in ovarian cancer using the tyrosine kinase inhibitor ZD 1839 (“Iressa”) Br J Most cancers 86(three):45662. 66. Aref AR, et al. (2013) Screening therapeutic EMT blocking agents inside of a three-dimensional microenvironment. Integr Biol (Camb) 5(2):38189. 67. Itoh N (2007) The Fgf households in individuals, mice, and zebrafish: Their evolutional processes and roles in development, metabolism, and disease. Biol Pharm Bull thirty(ten): 1819825. sixty eight. Turkington RC, et al. (2014) Fibroblast progress component receptor four (FGFR4): A targetable regulator of drug resistance in colorectal most cancers. Cell Death Dis five:e1046. 69. Miura S, et al. (2012) Fibroblast expansion issue 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma. BMC Most cancers twelve(56): fifteen. 70. Pel z-Garc A, et al. (2013) FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal most cancers. PLoS One eight(five):e63695. 71. Agarwal D, et al.; kConFab Investigators; Australian Ovarian Cancer 83-46-5 In stock Examine Group; GENICA Network; TNBCC (2014) FGF receptor genes and breast cancer susceptibility: Benefits within the Breast Cancer Affiliation Consortium. Br J Cancer a hundred and ten(4):1088100. 72. Cheng AL, Shen YC, Zhu AX (2011) Focusing on fibroblast growth element receptor signaling in hepatocellular carcinoma. Oncology 81(5-6):37280. 73. French DM, et al. (2012) Focusing on FGFR4 inhibits hepatocellular carcinoma in preclinical mouse products. PLoS 1 7(5):e36713. seventy four. Ito F (2011) Foreword. Target remedy for cancer: Anti-cancer medications targeting growthfactor signaling molecules. Biol Pharm Bull 34(12):1773. seventy five. Slattery ML, et al. (2013) Associations with advancement issue genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: The Breast Cancer Health Disparities Study. Breast Most cancers Res Treat 140(3):58701. 76. Kono SA, Marshall ME, Ware KE, Heasley LE (2009) The fibroblast advancement aspect receptor signaling pathway as a mediator of intrinsic resistance to EGFR-specific tyrosine kinase inhibitors in non-small cell lung cancer. Drug AAI101 生物活性 Resist Updat 12(4-5):9502. 77. Tai AL, et al. (2006) Co-overexpression of fibroblast expansion issue 3 and epidermal growth element receptor is correlated using the development of nonsmall cell lung carcinoma. Most cancers 106(1):14655. 78. Terai H, et al. (2013) Activation of your FGF2-FGFR1 autocrine pathway: A novel system of acquired resistance to gefitinib in NSCLC. Mol Most cancers Res eleven(7):75967. seventy nine. Ware KE, et al. (2010) Swiftly obtained resistance to EGFR tyrosine kinase inhibitors in NSCLC cell traces via de-repression of FGFR2 and FGFR3 expression. PLoS One 5(11):e14117. 80. Herrera-Abreu MT, et al. (2013) Parallel RNA interference screens establish EGFR activation as an escape system in FGFR3-mutant.